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Abstract 
 
 
Adrenaline  is  a  powerful  stimulus  of  glucagon  secretion.  It  acts  by  activation  of  β-adrenergic 
receptors but the downstream mechanisms have only been partially elucidated. Here we have 
examined the effects of adrenaline in mouse and human α-cells by a combination of 
electrophysiology, imaging of Ca2+  and PKA activity and hormone release measurements. We found 
that stimulation of glucagon secretion correlated with a PKA- and EPAC2-dependent (inhibited by PKI 
and  ESI-05,  respectively)  elevation  of  [Ca2+]i   in  α-cells,  which  occurred  without  stimulation  of 
electrical activity, persisted in the absence of extracellular Ca2+ but was sensitive to ryanodine, 
bafilomycin and thapsigargin. Adrenaline also increased [Ca2+]i in α-cells in human islets. Genetic or 
pharmacological inhibition of Tpc2  channel (that mediates Ca2+   release from acidic  intracellular 
stores) abolished the stimulatory effect of adrenaline on glucagon secretion and reduced the 
elevation of [Ca2+]i.. Furthermore, in Tpc2-deficient islets, ryanodine exerted no additive inhibitory 
effect. These data suggest that β-adrenergic stimulation of glucagon secretion is controlled by a 
hierarchy of [Ca2+]i signaling in the α-cell that is initiated by cAMP-induced Tpc2-dependent Ca
2+ 
release from the acidic stores and further amplified by Ca2+-induced Ca2+ release from the 
sarco/endoplasmic reticulum. 
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Introduction 
 
 
The  ability  of  the  ‘fight-or-flight’  hormone  adrenaline  to  increase  plasma  glucose  levels  by 
stimulating liver gluconeogenesis is in part mediated by glucagon, the body’s principal hyperglycemic 
hormone (1). Glucagon is secreted by the α-cells of the pancreas (2). Reduced autonomic stimulation 
of glucagon secretion may result in hypoglycemia, a serious and potentially fatal complication of 
diabetes (3). It has been estimated that up to 10% of insulin-treated patients die of hypoglycemia 
(4). Understanding the mechanism by which adrenaline stimulates glucagon secretion and how it 
becomes perturbed in diabetic patients is therefore essential. 
 
The  mechanism  by  which  adrenaline  stimulates  glucagon  secretion  has  only  partially  been 
elucidated. It is clear, however, that it involves activation of β-adrenergic receptors (5-7), leading to 
elevated intracellular cAMP ([cAMP]i), and culminates in elevation of the cytoplasmic free Ca
2+ 
concentration ([Ca2+]i) with resultant Ca
2+-dependent stimulation of glucagon secretion (6;8;9). 
However, our understanding of the spatiotemporal inter-relationship between different intracellular 
Ca2+ stores involved in the α-cell adrenaline signaling remains patchy. 
 
Here we have explored how adrenaline triggers glucagon release by a combination of hormone 
secretion measurements, electrophysiology and imaging of cytoplasmic Ca2+, cAMP and PKA activity 
in α-cells within intact mouse pancreatic islets. We have extended the measurements to human 
islets and also tested how the responsiveness to adrenaline is affected when islets are cultured 
under  hyperglycemic  conditions  to  establish  if  and  how  this  regulation  becomes  impaired  in 
diabetes. Our data indicate that Ca2+ release from acidic (lysosomal) stores plays a critical and 
unexpected role in adrenaline-induced glucagon secretion. 
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Research Design and Methods 
 
 
 
Chemicals 
 
The following substances were used (source given in parentheses): the L-type Ca2+  channel blocker 
isradipine and the P/Q Ca2+  channel blocker ω-agatoxin (Alomone Labs; Jerusalem, Israel); the α1- 
antagonist prazosin (Abcam, Cambridge, UK); the membrane-permeable PKA inhibitor myr-PKI, the 
IP3  receptor inhibitor Xestospongin C, the NAADP antagonist Ned-19, the V-ATPase inhibitor 
bafilomycin, the sER ATPase inhibitor thapsigargin and noradrenaline (Tocris Bioscience, Bristol, UK); 
the EPAC2 inhibitor ESI-05 (BioLog, Bremen, Germany); the insulin receptor antagonist (S961, Novo- 
Nordisk, Denmark). All other compounds were obtained from Sigma-Aldrich (Dorset, UK). 
 
Solutions 
 
The extracellular solution (EC1) used for imaging and current-clamp electrophysiology (Figure 2c) 
experiments contained (mM) 140 NaCl, 4.6 KCl, 2.6 CaCl2, 1.2 MgCl2, 1 NaH2PO4, 5 NaHCO3, 10 HEPES 
(pH 7.4, with NaOH). The pipette solution (IC1) consisted of (mM) 76 K2SO4, 10 NaCl, 10 KCl, 1 MgCl2, 
5 HEPES (pH 7.35 with KOH). The extracellular solution (EC2) for recordings of the depolarization- 
induced exocytosis (Figure 3c,d) contained (mM) 118 NaCl, 5.6 KCl, 2.6 CaCl2, 1.2 MgCl2, 5 HEPES, 20 
TEA-Cl and 6 glucose (pH 7.4 with NaOH). In the latter experiments, the pipette-filling medium (IC2) 
 
consisted of (mM) 76 Cs2SO4, 10 NaCl, 10 KCl, 1 MgCl2, 5 HEPES (pH 7.35 with CsOH). 
 
 
Animals, islet isolation and culture 
 
NMRI mice (Charles River) were used throughout the study except for the experiments involving the 
genetic  manipulation  of  TPC1  and  2  (Figure  5).  Tpcn1-/-   and  Tpcn2-/-   mice  were  developed  on 
C57Bl6/N background as described (10). Cd38-/- mice were developed on C57Bl6/J background (11). 
Age- and sex-matched C57BL6/N and C57Bl6/J wild-type animals were used as controls. Mice were 
kept in a conventional vivarium with a 12-hour-dark/12-hour-light cycle with free access to food and 
water and were killed by cervical dislocation. All experiments were conducted in accordance with 
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the United Kingdom Animals (Scientific Procedures) Act (1986) and the University of Oxford ethical 
guidelines. 
 
Pancreatic islets were isolated from mice by injecting collagenase solution into the bile duct, with 
subsequent digestion of the connective and exocrine pancreatic tissue. 
 
Human pancreatic islets were isolated in the Oxford Diabetes Research & Wellness Foundation 
 
Human Islet Isolation Facility according to published protocols (12;13). 
 
 
Unless otherwise stated, experiments were performed on acutely isolated islets. For experiments 
aiming to emulate chronic hyperglycemia, islets were cultured for 48h in RPMI medium containing 
30mM  or  the  standard  11mM  glucose,  supplemented  with  10%  FBS,  100IU/mL  penicillin  and 
 
100μg/mL streptomycin (all reagents from Life Technologies, Paisley, UK). Recombinant sensors 
were delivered via adenoviral (GCamp6, AKAR3) or BacMam (cADDis) vectors at 105 infectious units 
per islet, followed by 24-36h culturing at 11 mM glucose (as above) to express the sensors. 
 
Imaging of [Ca2+]i, cAMP and PKA activity in islet cells 
 
Time-lapse imaging of [Ca2+]i  in intact freshly isolated mouse islets was performed on an inverted 
Zeiss AxioVert 200 microscope equipped with Zeiss 510-META laser confocal scanning system. Prior 
to Ca2+ imaging, mouse islets were loaded with 6μM Fluo-4 at room temperature or 10 μM Fluo4FF 
(Molecular  Probes)  at  +37°C  for  90  min.  Both  dyes  were  excited  at  488nm  and  emission  was 
collected at 530nm, using 512x512 frame scanning mode with the pixel dwell time of 6μs (image 
frequency: 0.25Hz). Time-lapse imaging of [Ca2+]i  in groups of mouse islets was done on a 
Axiozoom.V16 microscope (0.1Hz) using Gcamp6f (14). 
 
PKA activity was reported in pancreatic islet cells using recombinant FRET probe AKAR3 (15). AKAR3 
 
CFP fluorescence was excited at 458nm using an Axiozoom.V16 microscope, which has been shown 
previously to excite CFP selectively (16); the emitted light was collected at 485nm (CFP) and 515nm 
(YFP) (image frequency: 0.0Hz). Time-lapse imaging of [cAMP]i  was performed using recombinant 
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Green Downward cADDis sensor (Montana Molecular, Bozeman, Montana, U.S.A.). The cADDis 
fluorescence was excited at 485nm and the emission recorded at 515nm using an Axiozoom.V16 
microscope. PKA and cAMP were imaged at a frequency of 16 mHz. 
 
All imaging at 34°C was performed using an open chamber. The bath solution containing various 
stimuli was perifused continuously at a rate of 200 μl/min. In experiments involving PKI, ESI-05, 
ryanodine, xestospongin C, Ned-19 thapsigargin and the Ca2+ channel blockers ω-agatoxin and 
isradipine, cells were preincubated in the solution of the respective agent for 90min. For the 
bafilomycin experiments, the pre-incubation time was 20 min. By pre-incubating the islets in the 
agonist/antagonist solutions we aimed to reach the saturation of the effect by the start of the 
recording. α-Cells were identified as those exhibiting a response to 1mM glutamate (Figure 1c-e) (17) 
and/or adrenaline (known to inhibit secretion of both insulin and somatostatin) (18). 
 
Images were acquired using ZenBlack or ZenBlue software (Carl Zeiss). 
 
 
Hormone release measurements 
 
Batches of 10–20 size-matched freshly isolated mouse islets were pre-incubated in 1ml of Krebs- 
Ringer buffer containing 1 mM glucose and 0.2% BSA for 30min at 37°C, followed by a 1-h test 
incubation in 1ml of the same medium supplemented as indicated. Glucagon was determined by RIA 
RIA (Eurodiagnostica, Malmo, Sweden) (19). The experiments on the Tpcn1, Tpcn2 or Cd38 knockout 
mice (Figure 5) and control mice were assayed using the MSD glucagon assay (Rockville, MD, USA). 
 
Electrophysiology 
 
The electrophysiological measurements were performed on α-cells within freshly isolated intact 
islets (from NMRI or C57Bl/6 mice), using an EPC-10 patch-clamp amplifier (HEKA Electronics, 
Lambrecht/Pfalz,   Germany)   and   Pulse   software.   All   electrophysiological   experiments   were 
performed at 34°C. α-Cells were identified as those active at low (3 mM) glucose and were 
differentiated from δ-cells (some of which fire action potentials, albeit at low frequency at this 
glucose  concentration)  by  the  distinct  appearance  of  action  potentials  (Figure  S2a).  For  the 
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membrane  potential  recordings  (Figure  2c),  the  perforated  patch  configuration  was  used  as 
described previously (20) using solutions IC1 and EC1. Exocytosis was measured as increases in 
membrane capacitance in α-cells in intact islets as described previously using the standard whole- 
cell configuration and IC2 and EC2. 
 
Data analysis 
Image sequences were analyzed (registration, background subtraction, ROI intensity vs time analysis, 
F/F0 calculation) using open-source FIJI software (http://fiji.sc/Fiji). The numerical data was analyzed 
 
using  IgorPro  package  (Wavemetrics).  To  calculate  partial  areas  under  the  curve  (pAUC),  the 
recording was split into 30s intervals, and area under the curve was computed for each individual 
interval (Figure S1c), using the trapezoidal integration. Numbers of measurements/cells are specified 
in Figure legends; the experiments on human islets were performed on islets isolated from 3 donors. 
Statistical analysis was performed using R (21). Data is presented as the mean values ± S.E.M. Mann- 
Whitney U-test or Wilcoxon’s paired test were used to compute the significance of difference 
between independent and dependent samples, respectively. Multiple comparisons within one 
experiment were performed using Kruskall-Wallis test with Nemenyi post-hoc analysis (independent 
samples) or Friedman test with Nemenyi post-hoc analysis (dependent samples). 
 
Results 
 
 
 
We tested the effect of adrenaline on glucagon secretion at a glucose concentration that roughly 
approximates hypoglycemia in vivo (3mM) (22) and minimizes the activity of β- and δ-cells (see (23) 
and (Figure S1b)). Adrenaline stimulated glucagon secretion from isolated mouse pancreatic islets by 
3.8±0.8-fold (Figure 1a), in line with previously reported results (5). 
 
 
 
Glucagon secretion is a Ca2+-dependent process and is stimulated by an elevation of [Ca2+]i  (5). We 
quantified  the  adrenaline  effect  on  [Ca2+]i   in  α-cells  within  intact  islets  using  time-lapse  laser 
scanning confocal microscopy. At 3mM glucose, <20% of the cells in pancreatic islets isolated from 
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NMRI mice were active and generated [Ca2+]i  oscillations (Figure 1b). Of the spontaneously active 
cells, over 70% responded to glutamate (Movie1) and were thus identified as α-cells (17;24). In α- 
cells  thus  identified,  adrenaline  induced  a  rapid and  reversible  increase  in  [Ca2+]i   (Figure  1c-e). 
Similar effects of adrenaline were observed at 1mM glucose (Figure S1a,e). 
 
The majority of the islet cells (>80%) were inactive at 3mM glucose but were stimulated when 
glucose was elevated to 20mM, as expected for β- or δ-cells cells (Figure 1e). At 3mM glucose, 
adrenaline did not affect [Ca2+]i  in any of these cells (Figure S1b) and at 20mM actually reduced 
[Ca2+]i     (not   shown).   Assessed   as   pAUC   (see   Research   Design   and   Methods;   Figure   S1c), 
responsiveness  to  adrenaline  strongly  correlated  with  spontaneous  [Ca2+]i   oscillations  at  3mM 
glucose (Pearson’s r=0.78) and responsiveness to glutamate (r=0.81) (Figure S1d). Similar responses 
to adrenaline and glutamate were observed in human islets (Figure 1d,f) and islets of C57Bl/6N mice 
(Figure 1f). These data make it unlikely that paracrine effects influence the [Ca2+]I responses to 
adrenaline in α-cells. Indeed, neither addition of exogenous insulin, nor inhibition of insulin receptor 
with S961 were able to significantly modify the adrenaline signaling in α-cells (Figure S5b). 
 
Glucagon-secreting α-cells are equipped with several types of voltage-gated Ca2+ channels (25). The 
effect of adrenaline on glucagon secretion was abolished by inhibition of L-type (with isradipine) but 
not P/Q-type (with ω-agatoxin) Ca2+  channels (Figure 2a). The changes in adrenaline-induced [Ca2+]i 
dynamics produced by isradipine and ω-agatoxin (Figure 2b) correlated with the effects of these 
blockers on glucagon secretion (Figure 2a). When isradipine was applied just before adrenaline, the 
response to adrenaline was attenuated but not abolished (Figure 2b). The effect of adrenaline on 
[Ca2+]i was mimicked by noradrenaline (released by intraislet adrenergic nerve endings (26)) and by 
the β-adrenergic agonist isoprenaline but abolished by β-antagonist propranolol. By contrast, the α1- 
adrenergic inhibitor prazosin, reported to inhibit the adrenaline-induced [Ca2+]i increases in single α- 
cells  (6),  had  no  detectable  effect  (Figure  2b).  Thus,  the  effect  of  adrenaline  on  α-cell  [Ca2+]i 
dynamics principally reflects activation of β-receptors. 
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We tested whether the adrenaline-induced increase in [Ca2+]i can be attributed to stimulation of α- 
cell action potential firing by whole-cell perforated-patch measurements (20). In agreement with the 
[Ca2+]i  measurements, α-cells were electrically active and fired action potentials at a frequency of 
~1Hz when exposed to 3mM glucose. Adrenaline depolarized α-cells by 3mV, produced a 10mV 
 
reduction of spike height (Figure 2c, Figure S2f), increased the duration of the action potential from 
 
4  to  8ms  but  did  not  (except  for  a  moderate  stimulation  during  the  initial  4s)  increase  spike 
frequency (Figure S2f,g). These small effects of adrenaline on α-cell electrical activity, possibly 
reflecting transient activation of a depolarizing store-operated membrane conductance following 
depletion of the sER Ca2+ stores (27), cannot account for the pronounced and sustained (several 
minutes) increases in [Ca2+]i  (Figure 1e,f). Indeed, neither hyperpolarizing the plasma membrane 
with KATP  channel opener diazoxide, nor chelating the extracellular Ca
2+  with EGTA prior to the 
addition of adrenaline diminished its capacity to increase [Ca2+]i in α-cells (Figure 2b, Figure S2c-e). 
 
β-Adrenergic signaling results in the Gs-mediated activation of adenylyl cyclase and hence increases 
the cytosolic concentration of cAMP ([cAMP]i  (28) (Figure S3 ), which in turn activates the 
downstream targets PKA and exchange protein directly activated by cAMP (EPAC2). We determined 
the  significance  of  PKA  and EPAC  in the  regulation of  [Ca2+]i   and glucagon secretion using the 
inhibitors myr-PKI (for PKA) and ESI-05 (for EPAC2). Both myr-PKI and ESI-05 inhibited adrenaline- 
induced glucagon secretion (Figure 3a) and significantly reduced the adrenaline-induced increase in 
[Ca2+]i  (Figure 3b), with ESI-05 exerting a much stronger effect than myr-PKI on glucagon secretion. 
The finding that EPAC2 and/or PKA, despite having similar effects on [Ca2+]i, differentially affect 
adrenaline-induced glucagon secretion (p<0.05), suggests that cAMP-dependent activation of EPAC2 
may be more tightly linked to exocytosis. 
 
The effects of adrenaline itself on glucagon secretion have previously been examined previously (5). 
Here we explored the roles of PKA and EPAC2 on the cAMP-dependent stimulation of the late-stage 
depolarization-evoked  exocytosis  (monitored  as  increases  in  membrane  capacitance).  Figure  3c 
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shows the increase in Cm evoked by a 20ms depolarization from -70 to 0mV, in the absence or 
presence of cAMP in the patch pipette and following inhibition of PKA or EPAC2; this pulse duration 
is comparable to that of the α-cell action potential (see Figure 2c). Under control conditions, 
exocytotic responses were small (<5fF). When cAMP was included in the pipette, exocytosis was 
stimulated by ~10-fold (Figure 3c). The stimulatory effect of cAMP on depolarization-evoked 
exocytosis was resistant to PKI but reduced by ESI-05 (Figure 3c,d). Longer depolarizations evoked 
larger exocytotic responses but the effects of cAMP and the inhibitors were the same (Figure S4 ). 
 
We explored the effect of adrenaline on [cAMP]i and its relationship to [Ca
2+]i further by imaging the 
activity of cAMP’s downstream target PKA using the FRET sensor AKAR3 (15). In most islet cells, the 
application of adrenaline reduced [cAMP]i (Figure S3 ), probably reflecting the effect of α2-adrenergic 
receptors in β- (29) and δ-cells (30). However, in a subset of islet cells (~10%, corresponding to α- 
cells), adrenaline increased [cAMP]i (Figure S3 c). These changes in [cAMP]i correlated with increased 
α-cell- and reduced β/δ-cell-activity of PKA (Figure 3e). We compared the adrenaline-induced 
increases in PKA activity in α-cells to that produced by increasing concentrations of the adenylyl 
cyclase  activator  forskolin  (Figure  3f-g).  Forskolin  dose-dependently  increased  PKA  activity  and 
[Ca2+]i;  half-maximal  effects  were  observed  at  0.19±0.05μM  and  5.3±1.5μM,  respectively.  The 
increase in PKA activity induced by 5μM adrenaline was equivalent to the effect of 4.2±1.1μM 
forskolin (Figure 3h), in agreement with the observation that stimulation of glucagon secretion is 
only seen at micromolar concentrations of adrenaline (5). The observation that the adrenaline- 
induced increase in [Ca2+]i requires high [cAMP]i (=high forskolin) is consistent with the involvement 
of EPAC2 (Kd for cAMP≈10
-5 M (31)) and the previous report that the stimulatory effect of adrenaline 
on glucagon secretion is dramatically reduced in EPAC2 knock-out islets (5). 
 
The findings that adrenaline produces a marked increase in [Ca2+]i despite having only a marginal 
effect on α-cell electrical activity and that it retains the capacity to stimulate glucagon secretion in 
the absence of extracellular Ca2+  and in the presence of a high concentration of the KATP  channel 
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activator diazoxide (to suppress electrical activity (20)) suggest that it, via activation of β-receptors 
and  cAMP-dependent  stimulation  of  PKA  and  EPAC2,  acts  by  mobilizing  Ca2+   from  intracellular 
stores. We tested for the capacity of adrenaline to induce glucagon secretion and increase [Ca2+]i in 
the presence of inhibitors of InsP3 receptor (xestospongin C (32)), sarco/endoplasmic reticulum (sER) 
Ca2+ ATPase (thapsigargin or CPA) and Ca2+-induced Ca2+-release (CICR; ryanodine). Ryanodine, 
xestospongin C and thapsigargin all inhibited the stimulatory effect of adrenaline on glucagon 
secretion (Figure 4a) but - unexpectedly - did not appear to affect the adrenaline-induced increase in 
[Ca2+]i (Figure S5a). We reasoned that there might be multiple Ca
2+ release mechanisms operating in 
parallel in the α-cell, and that Ca2+  release via any one of them might suffice to saturate the high- 
affinity Ca2+ dye Fluo-4 (which has a Kd for Ca
2+ of 300nM). Indeed, when the response to adrenaline 
was instead assayed using the low-affinity indicator Fluo-4FF (Kd=9.7μM), ryanodine as well as CPA 
produced marked and statistically significant diminution of the [Ca2+]i-increasing effect (Figure 4b,c). 
 
Prompted by the observations indicating the presence of a ryanodine-independent component in 
adrenaline-induced Ca2+  mobilization, we explored the possible involvement of acidic (lysosomal) 
Ca2+ stores (10) in this phenomenon. Bafilomycin, an inhibitor of the vacuolar type-H+ ATPase, 
abolished the adrenaline effect on [Ca2+]i in α-cells (Figure 4d). 
 
Ca2+ release from lysosomal stores is mediated by activation of Ca2+- and Na+-permeable (33;34) two- 
pore channels (TPCs) (10). We analyzed the role of these channels in the adrenaline-induced [Ca2+]i 
increase and glucagon secretion by generation of Tpcn1 or Tpcn2 knockout mice. The mRNA of both 
Tpcn1 and Tpcn2 is expressed in mouse and human α-cells (35-37). Whilst adrenaline increased 
[Ca2+]i in α-cells in islets isolated from Tpcn1
-/- mice (Figure 5a,d), it had very little effect in islets from 
Tpcn2-/- mice (Figure 5b,d). The effects of ablating TPC1 and TPC2 on [Ca2+]i correlated with those on 
glucagon secretion: adrenaline retained a stimulatory effect on glucagon secretion in Tpcn1-/- but not 
Tpcn2-/- islets (Figure 5c). The effect of adrenaline was seemingly smaller in Tpcn1-/- than in wild-type 
islets (but this difference did not attain statistical significance). Ryanodine had no inhibitory effect on 
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glucagon secretion in Tpcn2-/-  islets (Figure 5c). Likewise, pharmacological inhibition of NAADP (the 
intracellular messenger mobilizing lysosomal Ca2+  via TPC2 channels) (38;39), which inhibited 
glucagon secretion in wilt-type islets, had no effect in Tpcn2-/-  islets. Genetic ablation ADP-Ribosyl 
Cyclase  1  (CD38),  the  enzyme  producing  NAADP,  significantly  reduced  the  increase  in  [Ca2+]i 
produced by adrenaline (Figure 4d and Figure 5b) and abolished adrenaline-induced glucagon 
secretion (Figure 5c). 
 
Finally, we tested the effects of culturing islets at 30mM glucose for 72h (as an experimental 
paradigm of poorly controlled diabetes) on adrenaline’s capacity to elevate [Ca2+]I and stimulate 
glucagon secretion. ‘Hyperglycemia’ abolished the stimulatory action of adrenaline on both [Ca2+]i 
and glucagon secretion (Figure 6a-b,e). By contrast, islets cultured at 11mM glucose (close to the fed 
plasma glucose levels in mice) responded robustly to adrenaline with both a [Ca2+]i increase and 
stimulation of glucagon secretion. ‘Hyperglycemia’ did not affect the responsiveness to glutamate 
(Figure 6b) or effects of adrenaline on [cAMP]i and PKA activity (Figure 6c,d). 
 
Discussion 
 
 
Adrenaline-induced glucagon secretion involves both PKA- and EPAC2-dependent mechanisms (5). 
Here we have explored the downstream mechanisms with a focus on intracellular Ca2+  dynamics. 
Our data are suggestive of a hierarchy of intracellular Ca2+  signaling events and highlight a decisive 
role of lysosomal stores and NAADP-activated Ca2+ release via TPC2 channels. 
 
Pharmacological inhibition of EPAC2 nearly abolished the stimulatory effect of adrenaline on both 
glucagon secretion and [Ca2+]i. By contrast, inhibition of PKA, whilst lowering [Ca
2+]i  as strongly as 
inhibition of EPAC2, had only a moderate effect on glucagon secretion. This suggests that a full 
response   to   adrenaline   requires   the   activation   of   both   PKA-dependent   and   -independent 
mechanisms and that EPAC2 may act downstream of PKA (Figure 3c,d). 
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Given  the  weak  effect  of  adrenaline  on  α-cell  electrical  activity,  the  high  sensitivity  of  both 
adrenaline-induced glucagon secretion and [Ca2+]i  increase after inhibition of L-type Ca
2+  channels 
may seem paradoxical. However, this effect may be secondary to depletion of intracellular Ca2+ 
stores when Ca2+ entry is blocked. Indeed, adrenaline retained most of its effect on [Ca2+]i when 
isradipine was added just before adrenaline (Figure 2b). 
 
The mechanism by which adrenaline increases [Ca2+]i in α-cells has variably been attributed to 
increased Ca2+ channel activity (8) or activation of α1-adrenoreceptors (6). Our study unveils a 
previously unrecognized role of acidic Ca2+ stores in regulation of glucagon secretion. Ca2+ liberated 
by adrenaline-induced PKA and EPAC2 signaling from the acidic stores then triggers further Ca2+ 
increase by activating ryanodine-sensitive CICR (40). This hierarchy of intracellular [Ca2+]i signaling is 
supported by the fact that ryanodine exerts no additive inhibitory effect on glucagon secretion in 
Tpc2 knockout islets. 
 
Our data suggest a link between PKA/EPAC2 signaling and the Tpc2 channel activity and the NAADP 
antagonist Ned19 had no additive inhibitory effect on the adrenaline-induced [Ca2+]i increase when 
PKA and EPAC2 activity was pharmacologically suppressed (Figure 4d). The production of NAADP is 
influenced by high concentrations of cAMP, as expected for an effect mediated by low-affinity cAMP 
sensor EPAC2  and PKA-dependent phosphorylation of S66 in Tpc2 increases the channel’s open 
probability (41). The involvement of NAADP production is also illustrated by the ability of the genetic 
knockdown of the NAADP-generating enzyme CD38 to prevent the effects of adrenaline on both 
[Ca2+]i and glucagon secretion. NAADP-dependent adrenaline-induced Ca
2+ release via Tpc2 channels 
was recently implicated in the transduction of β-adrenergic signals in cardiomyocytes (42) but not 
pancreatic β-cells (43;44). The observation that Tpcn2-/- mice have normal fasting blood glucose (43) 
it not in conflict with the idea that adrenaline stimulates glucagon secretion by a TPC2-dependent 
mechanism as adrenaline itself will stimulate hepatic glucose production even in the absence of 
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glucagon and low glucose also stimulates glucagon secretion by a direct (intrinsic) mechanism 
independent of systemic signals (20;45). 
 
The innervation of mouse and human islets is rather different (46). The finding that adrenaline’s 
effects on [Ca2+]i  are essentially the same in mouse and human α-cells may seem at odds with the 
observation that adrenaline is without effect on glucagon secretion in human islets (23). It is likely 
that adrenaline produces a transient stimulation of glucagon secretion that escapes detection during 
a 1h incubation in human islets. We can exclude though that this discrepancy stems from different 
glucose concentrations used for secretion measurements (1 mM) and [Ca2+]i  imaging (3 mM). In a 
series  of initial experiments,  adrenaline  also increased  [Ca2+]i   in human islets  exposed  to 1mM 
glucose (Figure S1a). 
 
Circulating levels of adrenaline are below 1nM, and they remain below 100nM even during exercise 
(47). Interestingly, these low concentrations of adrenaline inhibit glucagon secretion whilst the 
stimulatory effect becomes detectable at concentrations >1μM and depends on activation of EPAC2 
(5). Such high levels of agonist are unlikely to occur anywhere except close to nerve terminals (48). 
Thus,  our  data  suggest  that  the  sympathetic  signal  mediated by  locally  released  noradrenaline 
(Figure  2b)  plays  a  key  role  in  linking  the  physiological  “flight-or-fight”  response  to  the  α-cell 
glucagon release. The schematic in Figure 7 presents a model for adrenaline signaling in pancreatic 
α-cells.  Hypoglycemia  elevates  systemic  adrenaline  (released  from  the  adrenal  glands)  and/or 
triggers a local release of noradrenaline from sympathetic nerve-endings within or adjacent to 
pancreatic islets. The catecholamine then binds to a β-adrenoreceptor on the α-cell, resulting in 
increased cytosolic cAMP levels, which activate PKA (which interacts with Tpc2 channel residing the 
membrane of the acidic vesicles) and EPAC2 (which facilitates the liberation of NAADP by CD38). The 
two signals converge into a release of Ca2+ from the acidic stores into the cytosol, which in turn 
triggers further liberation of Ca2+ from ER. Altogether, this leads to a four-fold stimulation of the 
glucagon release and, via stimulation of hepatic gluconeogenesis, rapid restoration of blood glucose 
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levels. This process depends on background electrical activity of the α-cell and plasmalemmal Ca2+ 
 
entry (explaining the effect of isradipine) to refill intracellular Ca2+ stores. 
 
 
The mechanism underlying the attenuation of the sympathoadrenal response in diabetes remains 
debated. Diabetes is associated with the loss of sympathetic islet innervation and this may, via 
reduced glucagon secretion, account for the increased risk of hypoglycemia (49). It is therefore of 
interest that our in vitro model of chronic hyperglycemia lowers the α-cell’s intrinsic responsiveness 
to adrenaline (Figure 6) and thus can itself result in the sympathetic islet neuropathy. The exact 
mechanism remains to be identified but is likely to be downstream of cAMP and activation of PKA, 
which were both unaffected. Novel therapeutic strategies that bypass the innervation may help to 
restore normal counter-regulation in diabetic patients. 
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Figure legends 
 
 
 
 
 
Figure 1 The stimulatory effect of adrenaline on glucagon secretion is mediated by 
selective elevation of [Ca2+]i in pancreatic α-cells 
(a) Glucagon secreted from isolated NMRI mouse islets in response to 3mM glucose with/without 
 
5μM adrenaline. #p<0.05 vs the effect of 3 mM glucose alone. (b) Variance of the Fluo4 intensity 
when the islet was perifused with 3mM glucose ± 5μM adrenaline or 20mM glucose (as indicated). 
The brighter cells are those in which [Ca2+]i oscillates. The arrow indicates a cell that started spiking 
after adrenaline had been applied. (c-d) Typical single α-cell responses to application of 1mM 
glutamate and 5μM adrenaline recorded in mouse (c; n=29) and human (d; n=55) islets, at 3mM 
glucose.  (e)  Representative  [Ca2+]i   timecourse  in  the  populations  of  α-  (n=21)  and  non-α-cells 
(mostly, β-cells, n=75), differentiated by the response to glutamate. The difference in magnitude of 
the glutamate and the adrenaline effects was not a consistent finding. (f) [Ca2+]i  changes in α-cells 
quantified as pAUC at 3mM glucose ± glutamate or adrenaline in mouse (NMRI, C57Bl/6N) and 
human islets. p<0.05 vs the respective effect observed in NMRI mice (*) or the effect of the basal (3 
mM glucose) in the same recording (#). 
 
 
 
 
 
Figure 2 Adrenaline’s effect in pancreatic α-cells depends on Ca2+  influx through L-type 
 
Ca2+ channels and is mediated by β-adrenergic signaling 
 
(a) Glucagon secreted from isolated NMRI mouse islets in response to 3 mM glucose with(out) 5μM 
adrenaline ± isradipine or ω-agatoxin (as indicated). p<0.05 vs the effect of adrenaline  + 3mM 
glucose (*) or vs the basal (3mM glucose + respective antagonist) group. (b) [Ca2+]i upon adrenergic 
(isoprenaline (n=27), or noradrenaline (n=19)) stimulation alone (n=29) or with (as indicated) 
isradipine (n=17, preincubated, n=29, acute), ω-agatoxin (n=13), propranolol (n=11), prazosin (n=49), 
diazoxide (n=20), EGTA (n=84). p<0.05 vs. the effect of adrenaline alone (*) or vs the basal (3 mM 
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glucose+respective (ant)agonist) of the same recording. (c) Effect of adrenaline on α-cell action 
potential firing (representative of 11 experiments). Examples of action potentials recorded in the 
absence and presence of adrenaline (taken from the recording above as indicated) are shown. 
 
 
 
 
 
Figure 3 Adrenaline mediates its effects via elevation of [cAMP]i 
 
(a) Glucagon secretion from isolated NMRI mouse islets in response to 3mM glucose. Adrenaline, 
myr-PKI  or  ESI-05  was  added  as  indicated.  p<0.05    vs  the  basal  (3  mM  glucose  +  respective 
antagonist) (#), vs the effect of 3 mM glucose + adrenaline (*) or vs the effect of 3mM glucose + 
adrenaline in the presence of ESI-05 (¶). (b) [Ca2+]i  upon application of (as indicated) adrenaline ± 
myr-PKI (n=32) or ESI-05 (n=12).  p<0.05 vs the basal of the same recording (#) or vs the effect of 3 
mM glucose + adrenaline (*). (c) Representative recording of the depolarization-induced increases in 
plasma membrane electrical capacitance. (d) Exocytosis in α-cells. The pipette solution contained (as 
indicated) either no cAMP (n=7) or 0.1mM cAMP (n=11) and PKA (1μM PKI, n=32) or EPAC2 (25μM 
ESI-05, n=11).   p<0.05   vs the effect of addition of cAMP into the pipette solution (*) and vs the 
control (cAMP-free) condition (#). (e) The effect of adrenaline on PKA activity in α- (n=22) and β-cells 
(n=85) within pancreatic islet cells isolated from Glu-RFP mice imaged using AKAR-3 sensor on 
LSM510 confocal microscope (see also Figure S3 ). The PKA activity is expressed as a change of the 
FRET ratio of the AKAR-3 sensor. (f) Comparison of the effects of 5μM adrenaline and 1nM-10μM 
forskolin on PKA activity of pancreatic islet cells (n=870). The excerpt (below, n=62) represents the 
data from cells activated by adrenaline (α-cells, see Figure 3e). Note the higher sensitivity of α-cells 
to forskolin: EC50=187±50nM (n=24) and 383±7 nM (n=807) for α- and β-cells, respectively. (g) 
Representative concentration-PKA activation dependence of [Ca2+]i on forskolin in α-cells measured 
using  Fluo4.  (h)  Forskolin  concentration-activation  curves  for  PKA  (solid  line,  n=98)  and  [Ca2+]i 
(dashed line, n=20). The effect of 5μM adrenaline on PKA measured on the same cells is mapped on 
to the curves as a shaded area (4.1±0.8μM forskolin). 
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Figure 4 Adrenaline-induced glucagon secretion involves intracellular Ca2+ release 
 
(a) Glucagon secreted from isolated NMRI mouse islets at 3mM with or without adrenaline and 
ryanodine, xestospongin C or thapsigargin as indicated.  p<0.05 vs the basal (#) or vs the effect of 
glucose + adrenaline (*).  (b) Representative recording of the effect of ryanodine on adrenaline- 
induced [Ca2+]i increases visualized using Fluo4FF. The control (dashed) is superimposed with the 
experimental trace. (c) [Ca2+]i upon adrenaline stimulation alone (n=23) or in the presence of 
ryanodine (n=22), xestospongin C (n=30) or CPA (n=14), as measured using Fluo4FF. (d) [Ca2+]i upon 
adrenaline stimulation alone or in the presence of Ned-19 (n=28), bafilomycin (n=36), myr-PKI and 
ESI-05 (n=31) or myr-PKI + ESI-05 + Ned-19 (n=21).  p<0.05 vs the basal (3 mM glucose + antagonist) 
of the same recording (#) or vs the effect of 3 mM glucose + adrenaline (*). Non-significant (p>0.1) vs 
the effect of 3mM glucose + adrenaline in the presence of PKI and ESI-05 (§). 
 
 
 
 
 
Figure 5 CD38 and TPC2 but not TPC1 mediate the adrenaline response in α-cells 
 
(a) Effect of adrenaline on [Ca2+]i in α-cells within islets isolated from TPC1-/- or TPC2-/- mice as 
indicated. (b) [Ca2+]i upon adrenaline stimulation in wild-type, TPC1-/- (n=84), TPC2-/- (n=27) or CD38-/- 
(n=153) mouse α-cells.  p<0.05 vs basal (3 mM glucose) of the same recording (#) or vs the effect of 
3mM glucose + adrenaline in wild-type animals (§). (c) Glucagon secretion from isolated mouse islets 
in response to low glucose (3mM) or adrenaline in the absence/presence of Ned-19 or ryanodine, 
measured in wild-type C57Bl/6n and TPC1-/-, TPC2-/-  and CD38-/-  mice.  p<0.05 vs the basal (3 mM 
glucose) (#), vs the effect of 3 mM glucose + adrenaline within the same genotype (*) or vs the effect 
of 3mM glucose + adrenaline in wild-type animals (§). 
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Figure 6 The adrenaline effect is attenuated by chronic hyperglycemia 
 
(a) Typical [Ca2+]i responses to 5μM adrenaline recorded in mouse islet α-cells precultured at 11 mM 
(n=102) or 30 mM (n=146) glucose for 48 hours. (b) Quantification of the data presented in (a). 
p<0.05) vs the basal (3 mM glucose) of the same recording (#) or vs the effect of 3 mM glucose + 
adrenaline  in  islets  pre-cultured  in  11  mM  glucose  (¶).  (c)  cAMP  responses  to  adrenaline  in 
pancreatic islet α-cells pre-cultured at 11 (n=164) or 30mM (n=212) glucose. (d) PKA responses to 
adrenaline in pancreatic islet α-cells pre-cultured at 11 (n=1277) or 30 mM (n=1323) glucose. (e) 
Glucagon  secretion  from  pancreatic  islets  pre-cultured  at  11  (n=10)  or  30 mM  (n=10)  glucose. 
p<0.05) vs the basal (3 mM glucose) condition (#) or vs the respective effect in islets precultured in 
11 mM glucose (¶). 
 
 
 
 
 
 
Figure 7 Model of adrenaline-induced glucagon secretion. See main text for details. 
 
AC, adenylyl cyclase; Cav1.x, L-type voltage-gated Ca
2+ channel; Gs, G-protein, s α-subunit. See main 
text for description. 
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Figure 1 The stimulatory effect of adrenaline on glucagon secretion is mediated by selective elevation of 
[Ca2+]i in pancreatic α-cells  
(a) Glucagon secreted from isolated NMRI mouse islets in response to 3mM glucose with/without 5µM 
adrenaline. #p<0.05 vs the effect of 3 mM glucose alone. (b) Variance of the Fluo4 intensity when the islet 
was perifused with 3mM glucose ± 5µM adrenaline or 20mM glucose (as indicated). The brighter cells are 
those in which [Ca2+]i oscillates. The arrow indicates a cell that started spiking after adrenaline had been 
applied. (c-d) Typical single α-cell responses to application of 1mM glutamate and 5µM adrenaline recorded 
in mouse (c; n=29) and human (d; n=55) islets, at 3mM glucose. (e) Representative [Ca2+]i timecourse in 
the populations of α- (n=21) and non-α-cells (mostly, β-cells, n=75), differentiated by the response to 
glutamate. The difference in magnitude of the glutamate and the adrenaline effects was not a consistent 
finding. (f) [Ca2+]i changes in α-cells quantified as pAUC at 3mM glucose ± glutamate or adrenaline in 
mouse (NMRI, C57Bl/6N) and human islets. p<0.05 vs the respective effect observed in NMRI mice (*) or 
the effect of the basal (3 mM glucose) in the same recording (#).  
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Figure 2 Adrenaline’s effect in pancreatic α-cells depends on Ca2+ influx through L-type Ca2+ channels and 
is mediated by β-adrenergic signaling 
(a) Glucagon secreted from isolated NMRI mouse islets in response to 3 mM glucose with(out) 5µM 
adrenaline ± isradipine or ω-agatoxin (as indicated). p<0.05 vs the effect of adrenaline + 3mM glucose (*) 
or vs the basal (3mM glucose + respective antagonist) group. (b) [Ca2+]i upon adrenergic (isoprenaline 
(n=27), or noradrenaline (n=19)) stimulation alone (n=29) or with (as indicated) isradipine (n=17, 
preincubated, n=29, acute), ω-agatoxin (n=13), propranolol (n=11), prazosin (n=49), diazoxide (n=20), 
EGTA (n=84). p<0.05 vs. the effect of adrenaline alone (*) or vs the basal (3 mM glucose+respective 
(ant)agonist) of the same recording. (c) Effect of adrenaline on α-cell action potential firing (representative 
of 11 experiments). Examples of action potentials recorded in the absence and presence of adrenaline 
(taken from the recording above as indicated) are shown.  
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Figure 3 Adrenaline mediates its effects via elevation of [cAMP]i 
(a) Glucagon secretion from isolated NMRI mouse islets in response to 3mM glucose. Adrenaline, myr-PKI or 
ESI-05 was added as indicated. p<0.05  vs the basal (3 mM glucose + respective antagonist) (#), vs the 
effect of 3 mM glucose + adrenaline (*) or vs the effect of 3mM glucose + adrenaline in the presence of ESI-
05 (¶). (b) [Ca2+]i upon application of (as indicated) adrenaline ± myr-PKI (n=32) or ESI-05 
(n=12).  p<0.05 vs the basal of the same recording (#) or vs the effect of 3 mM glucose + adrenaline (*). 
(c) Representative recording of the depolarization-induced increases in plasma membrane electrical 
capacitance. (d) Exocytosis in α-cells. The pipette solution contained (as indicated) either no cAMP (n=7) or 
0.1mM cAMP (n=11) and PKA (1µM PKI, n=32) or EPAC2 (25µM ESI-05, n=11).  p<0.05  vs the effect of 
addition of cAMP into the pipette solution (*) and vs the control (cAMP-free) condition (#). (e) The effect of 
adrenaline on PKA activity in α- (n=22) and β-cells (n=85) within pancreatic islet cells isolated from Glu-RFP 
mice imaged using AKAR-3 sensor on LSM510 confocal microscope (see also Figure S3). The PKA activity is 
expressed as a change of the FRET ratio of the AKAR-3 sensor. (f) Comparison of the effects of 5µM 
adrenaline and 1nM 10µM forskolin on PKA activity of pancreatic islet cells (n=870). The excerpt (below, 
n=62) represents the data from cells activated by adrenaline (α-cells, see Figure 3e). Note the higher 
sensitivity of α-cells to forskolin: EC50=187±50nM (n=24) and 383±7 nM (n=807) for α- and β-cells, 
respectively. (g) Representative concentration-PKA activation dependence of [Ca2+]i on forskolin in α-cells 
measured using Fluo4. (h) Forskolin concentration-activation curves for PKA (solid line, n=98) and [Ca2+]i 
(dashed line, n=20). The effect of 5µM adrenaline on PKA measured on the same cells is mapped on to the 
curves as a shaded area (4.1±0.8µM forskolin). 
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Figure 4 Adrenaline- induced glucagon secretion involves intracellular Ca2+ release (a) Glucagon secreted 
from isolated NMRI mouse islets at 3mM with or without adrenaline and ryanodine, xestospongin C or 
thapsigargin as indicated.  p<0.05 vs the basal (#) or vs the effect of glucose + adrenaline (*).  (b) 
Representative recording of the effect of ryanodine on adrenaline-induced [Ca2+]i increases visualized using 
Fluo4FF. The control (dashed) is superimposed with the experimental trace. (c) [Ca2+]i upon adrenaline 
stimulation alone (n=23) or in the presence of ryanodine (n=22), xestospongin C (n=30) or CPA (n=14), as 
measured using Fluo4FF. (d) [Ca2+]i upon adrenaline stimulation alone or in the presence of Ned-19 
(n=28), bafilomycin (n=36), myr-PKI and ESI-05 (n=31) or myr-PKI + ESI-05 + Ned-19 (n=21).  p<0.05 
vs the basal (3 mM glucose + antagonist) of the same recording (#) or vs the effect of 3 mM glucose + 
adrenaline (*).   
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Figure 5 CD38 and TPC2 but not TPC1 mediate the adrenaline response in α-cells 
(a) Effect of adrenaline on [Ca2+]i in α-cells within islets isolated from TPC1-/- or TPC2-/- mice as indicated. 
(b) [Ca2+]i upon adrenaline stimulation in wild-type, TPC1-/- (n=84), TPC2-/- (n=27) or CD38-/- (n=153) 
mouse α-cells.  p<0.05 vs basal (3 mM glucose) of the same recording (#) or vs the effect of 3 mM glucose 
+ adrenaline (*). (c) Glucagon secretion from isolated mouse islets in response to low glucose (3mM) or 
adrenaline in the absence/presence of Ned-19 or ryanodine, measured in wild-type C57Bl/6n and TPC1-/-, 
TPC2-/- and CD38-/- mice.  p<0.05 vs the basal (3 mM glucose) (#), vs the effect of 3 mM glucose + 
adrenaline within the same genotype (*) or vs the effect of 3mM glucose + adrenaline in wild-type animals 
(§). 
 
 
Page 29 of 39 Diabetes
  
 
 
Figure 6 The adrenaline effect is attenuated by chronic hyperglycemia 
(a) Typical [Ca2+]i responses to 5µM adrenaline recorded in mouse islet α-cells precultured at 11 mM 
(n=102) or 30 mM (n=146) glucose for 48 hours. (b) Quantification of the data presented in (a).  p<0.05) 
vs the basal (3 mM glucose) of the same recording (#) or vs the effect of 3 mM glucose + adrenaline in 
islets pre-cultured in 11 mM glucose (¶). (c) cAMP responses to adrenaline in pancreatic islet α-cells pre-
cultured at 11 (n=164) or 30mM (n=212) glucose. (d) PKA responses to adrenaline in pancreatic islet α-cells 
pre-cultured at 11 (n=1277) or 30 mM (n=1323) glucose. (e) Glucagon secretion from pancreatic islets pre-
cultured at 11 (n=10) or 30 mM (n=10) glucose.  p<0.05) vs the basal (3 mM glucose) condition (#) or vs 
the respective effect in islets precultured in 11 mM glucose (¶).  
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Figure 7 Model of adrenaline-induced glucagon secretion. See main text for details. 
AC, adenylyl cyclase; Cav1.x, L-type voltage-gated Ca2+ channel; Gs, G-protein, s α-subunit. See main text 
for description. 
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Online Supplemental material 
Supplementary figure legends 
 
Figure S1 Partial area under the curve 
(a) Representative [Ca2+]i timecourse in α-cells (above) the populations of islet cells (below) showing 
the effect of the addition of adrenaline at 1 or 3 mM glucose. (b-c) Representative [Ca2+]i timecourse 
in the populations of: (b) glutamate/adrenaline responsive cells (α-cells) and δ-cells, as 
differentiated by glutamate response and expression of RFP, respectively, and (c) β-cells and δ-cells, 
in sst-RFP mice expressing GCamp3 ubiquitously. (d) Representative recording of [Ca2+]i dynamics 
processed and quantified as partial area under the curve (pAUC). The recording (above, red) is split 
into equal time intervals (as indicated by the dashed lines) and area under the curve is computed for 
each interval (blue). Note that pAUC is sensitive to changes in both Ca2+ frequency and amplitude 
changes (below). (e) Representative [Ca2+]i timecourse in human α-cells showing the effect of the 
addition of adrenaline at 1mM glucose. (f) 3-D plot of [Ca2+]i (pAUC) values recorded for each 
individual mouse α-cell in response to 3mM glucose alone or with glutamate or adrenaline, as 
indicated. The ideal correlation would assume that the individual cell values are positioned along the 
main diagonal of the “3 mM glucose”-“glutamate”-“adrenaline” cube.  
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 Figure S2 Stimulatory effect of adrenaline can be dissociated from α-cell electrical 
activity 
(a) Action potentials recorded from α- and δ -cells. Note that action potentials in δ-cells are much 
shorter than those in α-cells and that they are of much larger amplitude. Note that action potentials 
in δ-cells are fired at lower frequency than those in α-cells and that they are of much larger 
amplitude. The data was obtained from mouse islets, in which RFP was expressed under tissue-
specific promoters to mark α-cells or δ-cells, respectively. (b-d) Representative trace of the effect of 
the acute inhibition of L-type Ca2+ channels with isradipine (b), chelation of the extracellular Ca2+ 
with EGTA (c) or opening of K+ channels with diazoxide on the adrenaline response in the α-cell. (e) 
Quantification of the effect in (c, d), n=84, n=72, respectively.  p<0.05) differences vs the effect of 3 
mM glucose alone (¶) or basal (3 mM glucose+(ant)agonist) of the same recording (#). (f-g) Effect of 
isoprenaline on α-cell action potential frequency (f, above) and most negative interspike membrane 
potential (f, below; solid circles) and peak of the spike (f, below: open circles) (n=11). (g) Spike 
duration (n=3 recordings) in the absence and presence of adrenaline.  p<0.05 differences vs effect of 
3 mM glucose alone in the same recording (#). 
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 Figure S3 Adrenaline induces PKA increase specifically in pancreatic α-cells  
(a) Confocal images of Glu-RFP mouse islets expressing AKAR3 sensor; arrows indicate α-cells 
expressing AKAR3. (b) Changes in PKA activity (quantified as a fold increase of the AKAR3 FRET ratio) 
in α- and β-cells in response to forskolin and adrenaline as indicated. The bottom heat map 
represents the data from all the cells within the islet: each line represents the timecourse of an 
individual cell, color-coded according to the calibration bar to the right. (c) Effect of adrenaline on 
[cAMP]i in human pancreatic islets measured using the downward cADDis sensor and presented as a 
heat map. Populations of α-cells (cAMP increases in response to 5μM adrenaline) and β-cells (cAMP 
decreases in response to 5μM adrenaline) are clearly visible.  
 
  
Page 36 of 39Diabetes
 Page 37 of 39 Diabetes
 Figure S4 Effect of pulse duration on capacitance increase 
(a) Representative traces of capacitance increases in the presence/absence (n=11) of cAMP in the 
patch pipette, with or without (n=7) myr-PKI (n=32) and ESI-05 (n=11), in response to the 10ms, 
20ms, 200ms and 300ms depolarizations. (b) [Ca2+]i transients evoked by the depolarization steps in 
(a), imaged simultaneously with cell capacitance measurements. See Error! Reference source not 
found.c for responses to a shorter depolarization.  
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 Figure S5 Role of the Ca2+ release from ER and acute insulin  
(a) [Ca2+]i quantified as pAUC upon adrenaline stimulation alone or in the presence of ryanodine 
(n=56), xestospongin C (n=24), thapsigargin (n=23) as indicated. (b) [Ca2+]i quantified as pAUC 
recorded in α-cells  at 3mM glucose with or without 100nM insulin (n=20) or 10 μM S961 (n=20).  
p<0.05 differences vs the basal (3 mM glucose + antagonist) of the same recording (#). 
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 Movie1 Pharmacology of Ca2+ dynamics in pancreatic α-cells 
Timecourse of [Ca2+]i imaged in mouse islet of Langerhans using Fluo-4 dye on the confocal 
microscope using 40x objective (see Research Design and Methods). The intensity of the dye is 
coded using a color loo-up table, as indicated. Several cells (e.g. the one indicated by the arrow) 
display clear [Ca2+]i oscillations under basal (3 mM glucose) conditions. Subsequent additions of 
glutamate and adrenaline dramatically enhance Ca2+ dynamics in these cells.    
https://www.dropbox.com/s/gdqn8pdulwazfyc/Hamilton_et_al_movie_01.gif?dl=0 
 
 
Movie2 Adrenaline effect interacts with chronic hyperglycemia 
Timecourse of [Ca2+]i  imaged in groups of islets precultured at 11 or 30 mM glucose, as indicated, 
using recombinant sensor GCamp6f and imaged on a zoom microscope (see Research Design and 
Methods) 
https://www.dropbox.com/s/dblgi24bmurmc7c/Hamilton_et_al_movie_02.gif?dl=0 
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